Cargando…
Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated in January 2020 and, on March, the WHO declared the status of a pandemic. It causes a cytokine release syndrome, called “cytokine storm,” characterized by systemic inflammation involving elevated levels of cytokines and hypera...
Autores principales: | Barbara, Infante, Silvia, Mercuri, Dario, Troise, Giuseppe, Castellano, Stallone, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655874/ https://www.ncbi.nlm.nih.gov/pubmed/34901054 http://dx.doi.org/10.3389/fmed.2021.732792 |
Ejemplares similares
-
mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation
por: Granata, Simona, et al.
Publicado: (2023) -
Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020) -
Hypoxic State of Cells and Immunosenescence: A Focus on the Role of the HIF Signaling Pathway
por: Troise, Dario, et al.
Publicado: (2023) -
mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients
por: Netti, Giuseppe S., et al.
Publicado: (2022) -
Recent advances in molecular mechanisms of acute kidney injury in patients with diabetes mellitus
por: Infante, Barbara, et al.
Publicado: (2023)